The global preclinical imaging market is anticipated to grow at a CAGR of 6.82% during the forecast period (2023-2030). Preclinical imaging is a widely used tool in oncology, cardiovascular, neurology and neuroscience, and metabolic research. It is employed to visualize and monitor tumor growth, assess treatment responses, study heart function, vascular health, and cardiac diseases, investigate brain structure and function, track neurological diseases, study neurological disorders, and visualize metabolic processes and tissues. This helps researchers develop new cancer therapies, understand heart attacks and heart failure, investigate Alzheimer's disease and Parkinson's disease, and study metabolic pathways, diabetes, obesity, and related disorders. The market’s growth is attributed to development of drugs across the globe.
Browse the full report description of “Preclinical Imaging Market Size, Share & Trends Analysis Report by Product (MicroCT (Micro Computed Tomography), MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography), Ultrasound Imaging, Optical Imaging, Photoacoustic Imaging, and Others), by Application (Pharma and Biotech Companies, Research and Development, Neurology and Neuroscience, and Others), and by End-User (Pharma and Biotech Companies, Academic and Research Institutions, Hospitals and Medical Centers, Government Research Agencies, and Others) Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/preclinical-imaging-market
Advanced imaging systems are utilized by the pharmaceutical and biotechnology sectors to speed up drug research and assess possible therapies, to assist the industry expand. Accordingly, market players are coming up with new products to cater the demand for new preclinical imaging technology. For instance, in September 2023, Revvity, Inc. offers a number of innovative preclinical imaging technologies to assist researchers in making significant advances through the introduction of three systems, its improved imaging portfolio aims to encourage innovation across a range of preclinical research applications. The latest developments, such as the IVIS Spectrum 2 and IVIS SpectrumCT 2 imaging systems, significantly raise the bar for adaptability and sensitivity for in vivo optical imaging. The QuantumTM GX3 microCT structural imaging system, that has been developed to help researchers better understand disease biology or evaluate and expedite the development of treatment candidates, is additionally now available. It has higher resolution and speed for both in vivo and ex vivo imaging.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Product
o By Application
o By End-User
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Bruker Corp., Euro-BioImaging ERIC, FUJIFILM Holdings Corp., IVIM Technology Corp., Mediso Kft. and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Preclinical Imaging Market Report Segment
By Product
By Application
By End-User
Global Preclinical Imaging Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/preclinical-imaging-market